ArticleVeterinary research communications2025
Therapeutic application of canine adipose tissue-derived mesenchymal stromal cells in a dog with refractory immune-mediated thrombocytopenia, with diabetic ketoacidosis, and gastrointestinal bleeding induced by immunosuppressive treatment.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory immune-mediated thrombocytopenia (ITP) in dogs is a condition with a poor prognosis due to the poor response to immunosuppressive therapy and the adverse effects of long-term drug administration. This case report describes the successful management of refractory ITP using stem cell therapy in a dog that experienced severe side effects from immunosuppressive treatment. The patient experienced recurrent relapses when prednisolone (PDS) tapering was attempted during conventional immunosuppressive therapy, necessitating prolonged use of PDS; this led to complications, such as diabetic ketoacidosis and chronic gastrointestinal bleeding. In this case, the dog was treated with canine adipose tissue-derived mesenchymal stromal cells (cAT-MSCs) administered intravenously at four-week intervals for eight sessions. Following MSC therapy, refractory ITP was successfully treated without PDS, and the side effects associated with prolonged use of PDS and multiple immunosuppressants were resolved. Although further investigations are needed for the clinical application of cAT-derived MSCs in ITP, cAT-MSC injections could be an alternative treatment option for refractory ITP in veterinary medicine.
Indexed as
Identifiers
40875161What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.